Oral Abstract Session
Advancing Onconephrology Precision: Biomarkers, Therapeutic Targets, and Patient Outcomes
October 23, 2026 | 04:30 PM - 06:00 PM
Location: Room 401, Convention Center
Session Description
Oral Abstract Session
Learning Pathway(s)
- Onconephrology
Moderators
Presentations
A Light-Chain Amyloidosis Model in Kidney Organoids Demonstrates That Attenuation of CDK1-Mediated Epithelial-Mesenchymal Transition (EMT) Resolves Podocytopathy and Tubulointerstitial Fibrosis
Association of CT Body Composition Features with eGFR and Its Longitudinal Slope Among Patients Treated with Molecularly Targeted Cancer Therapies
Differential Nephrotoxicity of Antibody-Drug Conjugate Payloads: A Propensity Score-Matched Analysis of Monomethyl Auristatin E vs. Topoisomerase I Inhibitors
Longitudinal Biomarker Trends in Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
Multicenter Study of Risk Factors and Clinicopathological Characteristics of Chronic Lymphocytic Leukemia (CLL)-Related Kidney Lesions: Is CLL of Renal Significance?
Single-Cell RNA Sequencing of Kidney Tissue, Urine, and Blood of Patients with Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis Reveals Conserved T-Cell Populations
Urinary Proteomic Biomarker Profiling of AKI in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation
Discrepancy in Glomerular Filtration Rate in Patients with Cancer